UCB Pharma, Gmbh et al. v. Mylan, NV

21-2336 Fed. Cir. Closed 9 patents
Get a prior-art report

Infringement action filed 22 Sep 2021 in the United States Court of Appeals for the Federal Circuit and closed 12 Apr 2023, with 9 patents asserted. Recorded basis of termination: appeal dismissed.

Case recordPatsnap Litigation Data·

Case record

Case no.
21-2336
Verdict cause
Infringement action
Court
Fed. Cir.
Court level
Court of Appeals
Case region
District of Columbia
Judge
None recorded
Trial level
Appeal
Filed – Closed
22 Sep 2021 – 12 Apr 2023
Duration
567 days
Basis of termination
Appeal Dismissed
Products & marks
Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
Source: Patsnap Litigation Data. Case 21-2336, United States Court of Appeals for the Federal Circuit. Open this record in Eureka
Patsnap Eureka

Check this patent against your own product

Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.

Get an FTO claim chart
10,000 free credits to start
Patent at issue
US6699498B1 Inactive App. US09/723130

Transdermal therapeutic systems having improved stability and their production

This invention provides for, inter alia, a transdermal therapeutic system comprising at least one therapeutically active substance, which is oxidizable by hydroperoxides, wherein the amount of oxidative degradation of said active substances(s) and the corresponding formation of oxidative degradation products is reduced, which comprises one or more constituents of said transdermal therapeutic system being in contact with said active substance(s), wherein the sum of the peroxide number(s) (PON) of each of said constituents related to their percentage of the whole amount of said constituents as expressed by the formulawhereN is the percentage content of the whole amount of said constituents in the TTS,n is the number of said constituents in the TTS,i is the running numberPON is the peroxide number of each of the constituents,is not greater than 20.

Read claims and description in Eureka
Patent standing
Legal status
Inactive
Granted
2 Mar 2004
Earliest priority
29 Nov 1999
Est. expiry
27 Nov 2020
Validity challenges
None recorded
Licences recorded
None recorded
Classification
A61K9/70A61K9/06A61K31/565A61K47/04A61K47/06A61K47/10A61K47/12A61K47/14A61K47/30A61K47/32A61L15/44A61L15/58A61P15/00
Prosecution counsel
HAUG PARTNERS LLP
US7413747B2 Inactive App. US11/931666

Transdermal therapeutic system for treating Parkinsonism

A transdermal therapeutic system (TTS) comprises a silicone-based polymer adhesive system having distributed therein (−)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol free base in an amount of about 5% to 40% by weight. The adhesive system comprises a silicone adhesive and an additive having increased solubility for the active substance, in an amount effective to increase dissolving capacity of the matrix for the active substance.

Read claims and description in Eureka
Patent standing
Legal status
Inactive
Granted
19 Aug 2008
Earliest priority
30 Mar 1998
Est. expiry
18 Mar 2019
Validity challenges
None recorded
Licences recorded
None recorded
Classification
A61F13/02A61F13/00A61K9/14A61L15/16A61K9/70A61K31/381A61P25/16A61P43/00
Prosecution counsel
Harness Dickey
US7413747B2 patent drawing, figure 1
Fig. 1 · US7413747B2, from the published patent document
US7413747B2 patent drawing, figure 2
Fig. 2 · US7413747B2, from the published patent document
Source: Patsnap patent data + case record. Bibliographic fields and drawings reproduced from the published patent document. Break down the claims
Parties & counsel

Parties of record

Plaintiff

UCB Pharma, Gmbh

Core tech
Not recorded
Counsel
Alexa Hansen · Anthony D. Raucci Esq. · Brian Gerard Bieluch · Catherine McCord · Derek J. Fahnestock · George Frank Pappas · Jack B. Blumenfeld · James Trainor · Kevin McGann · Michael E. Bowlus · Richard L. Rainey · Silvia Medina
Firm
Covington & Burling LLP, Fenwick & West LLP, Morris, Nichols, Arsht & Tunnell LLP
Also named
LTS Lohmann Therapie-Systeme, AG · UCB Pharma, Gmbh

Counsel of record

Source: case record + Patsnap company data. Attorney names appear as recorded in the docket. Compare both portfolios
Outcome

Basis of termination

From the record · verbatim

"THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED"

Case 21-2336 · Fed. Cir. · closed 12 April 2023
Source: case record, verbatim. The quoted paragraph is the basis-of-termination text as filed.

Related cases

Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.

FAQ

Frequently asked questions

What is case 21-2336?

21-2336 is a patent infringement action brought by UCB Pharma, Gmbh against Mylan, NV, filed on 22 Sep 2021 in the United States Court of Appeals for the Federal Circuit. The case closed on 12 April 2023.

Which patents were asserted in 21-2336?

US6699498B1 (“Transdermal therapeutic systems having improved stability and their production”), assigned to LTS LOHMANN THERAPIE-SYSTEME AG, currently inactive; US7413747B2 (“Transdermal therapeutic system for treating Parkinsonism”), assigned to UCB MANUFACTURING IRELAND LIMITED, currently inactive; US8246979B2 (“Transdermal delivery system for the administration of rotigotine”), assigned to UCB PHARMA GMBH; US8246980B2 (“Transdermal delivery system”), assigned to UCB PHARMA GMBH; US9925150B2 (“Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine”), assigned to UCB PHARMA GMBH|LTS LOHMANN THERAPIE SYSTEME AG; US10130589B2 (“Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine”), assigned to UCB PHARMA GMBH|LTS LOHMANN THERAPIE SYSTEME AG; US8617591B2 (“Transdermal delivery system for the administration of rotigotine”), assigned to UCB PHARMA GMBH; US10350174B2 (“Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine”), assigned to UCB PHARMA GMBH|LTS LOHMANN THERAPIE SYSTEME AG; US6884434B1 (“Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof”), assigned to UCB MANUFACTURING IRELAND LIMITED|LTS LOHMANN THERAPIE-SYSTEME AG. The record also lists Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine.

How was case 21-2336 terminated?

The recorded basis of termination is appeal dismissed. The termination text reads: "THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED"

How long did case 21-2336 take?

567 calendar days, from filing on 22 Sep 2021 to closure on 12 April 2023.

Who were the attorneys and the judge in 21-2336?

Alexa Hansen, Anthony D. Raucci Esq., Brian Gerard Bieluch, Catherine McCord, Derek J. Fahnestock, George Frank Pappas, Jack B. Blumenfeld, James Trainor, Kevin McGann, Michael E. Bowlus, Richard L. Rainey and Silvia Medina are recorded as counsel for plaintiff UCB Pharma. Deepro Mukerjee, Eric Thomas Werlinger, Jillian Schurr, Jitendra Malik , Esq. and Lance Soderstrom appear for defendant Mylan.

Answers reproduce fields from the case record for 21-2336 and do not constitute legal advice. Ask your own question

General information only. This page reproduces publicly available court docket data for case 21-2336 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such. It does not create an attorney-client relationship.

Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.

No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed. The filing of a claim is not a court finding, and a docket marked “closed” does not by itself establish infringement, validity, settlement or a decision on the merits.

No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.

Third-party names and marks. Party, attorney, judge and company names appear for identification only. Company names may be trademarks of their owners; their appearance does not, by itself, imply affiliation with or endorsement by Patsnap.

Patent figures. Any patent drawings shown are reproduced from the identified patent publications to illustrate the cited documents, and do not establish the scope, validity or enforceability of any patent.

Corrections and privacy requests. To report an inaccurate record or attribution, use the “Report an incorrect record” link on this page. For requests concerning your personal information — including, where applicable, the rights to access, rectify, erase, restrict or object to processing — use the “Privacy request” link. We assess requests under applicable law. See our Privacy Policy for details of this processing.

Help us improve

Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.